Carlo Brugnara

List of Publications by Year
in descending order

227 papers	14,668 citations	18482 62 h-index	20358 116 g-index
253 all docs	253 docs citations	253 times ranked	15277 citing authors

#	Article	IF	Citations
1	Standardization of reticulocyte counts in the athlete biological passport: A practical update. International Journal of Laboratory Hematology, 2022, 44, 112-117.	1.3	5
2	Purinergic signaling is essential for full Psickle activation by hypoxia and by normoxic acid pH in mature human sickle red cells and in vitro-differentiated cultured human sickle reticulocytes. Pflugers Archiv European Journal of Physiology, 2022, 474, 553-565.	2.8	1
3	Erythroidâ€specific inactivation of Slc12a6/Kcc3 by EpoR promoterâ€driven Cre expression reduces Kâ€Cl cotransport activity in mouse erythrocytes. Physiological Reports, 2022, 10, e15186.	1.7	2
4	Commentaries on Viewpoint: Consider iron status when making sex comparisons in human physiology. Journal of Applied Physiology, 2022, 132, 703-709.	2.5	1
5	The Erythrocyte, a Novel Disease-Mediator for COVID-19 Vasculopathy?. JACC Basic To Translational Science, 2022, 7, 205-206.	4.1	1
6	The erythroid K-Cl cotransport inhibitor [(dihydroindenyl)oxy]acetic acid blocks erythroid Ca²⁺-activated K⁺ channel KCNN4. American Journal of Physiology - Cell Physiology, 2022, 323, C694-C705.	4.6	2
7	Potential causal role of l-glutamine in sickle cell disease painful crises: A Mendelian randomization analysis. Blood Cells, Molecules, and Diseases, 2021, 86, 102504.	1.4	14
8	Haemoglobin response to senicapoc in patients with sickle cell disease: a reâ€analysis of the Phase III trial. British Journal of Haematology, 2021, 192, e129-e132.	2.5	15
9	Plasmodium vivax infection compromises reticulocyte stability. Nature Communications, 2021, 12, 1629.	12.8	19
10	Less (Fe) is more (Hb) in SCA. Blood, 2021, 137, 1446-1447.	1.4	1
11	Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with nonâ€transfusionâ€dependent Î²â€thalassaemia. British Journal of Haematology, 2021, 194, 474-477.	2.5	10
12	Single-cell analysis of FOXP3 deficiencies in humans and mice unmasks intrinsic and extrinsic CD4+ T cell perturbations. Nature Immunology, 2021, 22, 607-619.	14.5	35
13	The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a Î²-thalassemia mouse model. Journal of Clinical Investigation, 2021, 131, .	8.2	39
14	Dietary Ï‰-3 Fatty Acid Supplementation Improves Murine Sickle Cell Bone Disease and Reprograms Adipogenesis. Antioxidants, 2021, 10, 799.	5.1	3
15	A <i>Grammastola spatulata</i> mechanotoxin-4 (GsMTx4)-sensitive cation channel mediates increased cation permeability in human hereditary spherocytosis of multiple genetic etiologies. Haematologica, 2021, 106, 2759-2762.	3.5	5
16	Using Reticulocyte Hemoglobin Equivalent as a Marker for Iron Deficiency and Responsiveness to Iron Therapy. Mayo Clinic Proceedings, 2021, 96, 1510-1519.	3.0	13
17	Global genome analysis reveals a vast and dynamic anellovirus landscape within the human virome. Cell Host and Microbe, 2021, 29, 1305-1315.e6.	11.0	59
18	An artificial intelligenceâ€assisted diagnostic platform for rapid nearâ€patient hematology. American Journal of Hematology, 2021, 96, 1264-1274.	4.1	22

#	Article	IF	Citations
19	Diagnostics with modern genomics. American Journal of Hematology, 2021, 96, E447.	4.1	0
20	Trpv1 and Trpa1 are not essential for Psickle-like activity in red cells of the SAD mouse model of sickle cell disease. Blood Cells, Molecules, and Diseases, 2021, 92, 102619.	1.4	1
21	Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2020, 81, 102389.	1.4	5
22	Pediatric hematology normal ranges derived from pediatric primary care patients. American Journal of Hematology, 2020, 95, E255.	4.1	9
23	Non-Parametric Combined Reference Regions and Prediction of Clinical Risk. Clinical Chemistry, 2020, 66, 363-372.	3.2	2
24	Association of Blood Type With Postsurgical Mucosal Bleeding in Pediatric Patients Undergoing Tonsillectomy With or Without Adenoidectomy. JAMA Network Open, 2020, 3, e201804.	5.9	3
25	Measuring Reticulocyte Hemoglobin Content As a Marker for Iron Deficiency and Response to Therapy Represents a Paradigm Shift in Care. Blood, 2020, 136, 42-43.	1.4	0
26	The Pyruvate Kinase Activator Mitapivat Ameliorates Anemia and Prevents Iron Overload in a Mouse Model of Hereditary Spherocytosis. Blood, 2020, 136, 29-29.	1.4	3
27	Combined genetic disruption of K-Cl cotransporters and Gardos channel KCNN4 rescues erythrocyte dehydration in the SAD mouse model of sickle cell disease. Blood Cells, Molecules, and Diseases, 2019, 79, 102346.	1.4	11
28	Heritability of fetal hemoglobin, white cell count, and other clinical traits from a sickle cell disease family cohort. American Journal of Hematology, 2019, 94, 522-527.	4.1	6
29	Monitoring of blood coagulation with nonâ€contact drop oscillation rheometry. Journal of Thrombosis and Haemostasis, 2019, 17, 1345-1353.	3.8	4
30	Erythrocyte ion content and dehydration modulate maximal Gardos channel activity in KCNN4 V282M/+ hereditary xerocytosis red cells. American Journal of Physiology - Cell Physiology, 2019, 317, C287-C302.	4.6	11
31	Laboratory Assessment of Iron Status. , 2019, , 51-68.		0
32	Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nature Medicine, 2019, 25, 776-783.	30.7	344
33	Resolution of sickle cell diseaseâ€“associated inflammation and tissue damage with 17R-resolvin D1. Blood, 2019, 133, 252-265.	1.4	50
34	Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of Î²-thalassemia. JCI Insight, 2019, 4, .	5.0	19
35	Sickle cell dehydration: Pathophysiology and therapeutic applications. Clinical Hemorheology and Microcirculation, 2018, 68, 187-204.	1.7	33
36	1 EFFECTIVENESS OF ORAL IRON SUPPLEMENTATION IN THE TREATMENT OF ANEMIA ASSOCIATED WITH PEDIATRIC ULCERATIVE COLITIS FLARE. Gastroenterology, 2018, 154, S75.	1.3	0

#	Article	IF	Citations
37	Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?. American Journal of Nephrology, 2018, 47, 72-83.	3.1	65
38	Iron balance and iron supplementation for the female athlete: A practical approach. European Journal of Sport Science, 2018, 18, 295-305.	2.7	67
39	Revised prevalence estimate of possible Hereditary Xerocytosis as derived from a large U.S. Laboratory database. American Journal of Hematology, 2018, 93, E9-E12.	4.1	13
40	Shape oscillations of single blood drops: applications to human blood and sickle cell disease. Scientific Reports, 2018, 8, 16794.	3.3	19
41	Genotypeâ€phenotype correlation and risk stratification in a cohort of 123 hereditary stomatocytosis patients. American Journal of Hematology, 2018, 93, 1509-1517.	4.1	48
42	Erythrocytes lacking the Langereis blood group protein ABCB6 are resistant to the malaria parasite Plasmodium falciparum. Communications Biology, 2018, 1, 45.	4.4	17
43	A common functional PIEZO1 deletion allele associates with red blood cell density in sickle cell disease patients. American Journal of Hematology, 2018, 93, E362-E365.	4.1	15
44	Increased Red Cell KCNN4 Activity in Sporadic Hereditary Xerocytosis Associated With Enhanced Single Channel Pressure Sensitivity of PIEZO1ÂMutant V598M. HemaSphere, 2018, 2, e55.	2.7	10
45	Imatinib Protects Against Hypoxia/Reoxygenation Induced Lung and Kidney Injury in a Humanized Mouse Model for SCD. Blood, 2018, 132, 725-725.	1.4	1
46	Highly Efficient Therapeutic Gene Editing of BCL11A enhancer in Human Hematopoietic Stem Cells from ÃŸ-Hemoglobinopathy Patients for Fetal Hemoglobin Induction. Blood, 2018, 132, 3482-3482.	1.4	2
47	Optimized Beta-Globin Expression and Enucleation from Induced Red Blood Cells for In Vitro Modeling of Sickle Cell Disease. Blood, 2018, 132, 2359-2359.	1.4	0
48	Dietary Omega-3 Fatty Acid Supplementation Improves Sickle Cell Bone Disease By Affecting Osteoblastogenesis and Adipogenesis. Blood, 2018, 132, 2356-2356.	1.4	0
49	Variant-aware saturating mutagenesis using multiple Cas9 nucleases identifies regulatory elements at trait-associated loci. Nature Genetics, 2017, 49, 625-634.	21.4	96
50	Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channelâ€like activity inhibited by senicapoc. American Journal of Hematology, 2017, 92, E108-E110.	4.1	21
51	Genome-wide association study of erythrocyte density in sickle cell disease patients. Blood Cells, Molecules, and Diseases, 2017, 65, 60-65.	1.4	13
52	Haematological Responses to Detraining Following the Boston Marathon. Medicine and Science in Sports and Exercise, 2017, 49, 331-332.	0.4	2
53	Knowledge of Blood Group Decreases von Willebrand Factor Panel Testing in Children. HemaSphere, 2017, 1, e3.	2.7	3
54	The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity. Antimicrobial Agents and Chemotherapy, 2016, 60, 613-616.	3.2	8

#	Article	IF	Citations
55	Diagnosis of iron deficiency anemia using density-based fractionation of red blood cells. Lab on A Chip, 2016, 16, 3929-3939.	6.0	22
56	Functional characterization of novel ABCB6 mutations and their clinical implications in familial pseudohyperkalemia. Haematologica, 2016, 101, 909-917.	3.5	30
57	The American Journal of Hematology turns 40. American Journal of Hematology, 2016, 91, 4-4.	4.1	1
58	Targeted Application of Human Genetic Variation Can Improve Red Blood Cell Production from Stem Cells. Cell Stem Cell, 2016, 18, 73-78.	11.1	78
59	A Selective ORAL GLYT1 Inhibitor, Improves Anemia and RED CELL Survival in a MOUSE MODEL of Beta-Thalassemia. Blood, 2016, 128, 1284-1284.	1.4	0
60	AmericanJournal ofHematology, getting ready for the 40th birthday in 2016. American Journal of Hematology, 2015, 90, 1-1.	4.1	5
61	2015 Clinical trials update in sickle cell anemia. American Journal of Hematology, 2015, 90, 934-950.	4.1	34
62	Dietary Â-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease. Haematologica, 2015, 100, 870-880.	3.5	51
63	Novel Gardos channel mutations linked to dehydrated hereditary stomatocytosis (xerocytosis). American Journal of Hematology, 2015, 90, 921-926.	4.1	81
64	Reductions in Red Blood Cell 2,3-Diphosphoglycerate Concentration during Continuous Renal Replacment Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 74-79.	4.5	29
65	Automated Hematology Analyzers: State of the Art. Clinics in Laboratory Medicine, 2015, 35, xiii-xiv.	1.4	5
66	A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion. Science, 2015, 348, 711-714.	12.6	107
67	The utility of the DDAVP challenge test in children with low von Willebrand factor. British Journal of Haematology, 2015, 170, 884-886.	2.5	5
68	Diagnosis of iron-deficient states. Critical Reviews in Clinical Laboratory Sciences, 2015, 52, 256-272.	6.1	57
69	Clinical Utility of Reticulocyte Parameters. Clinics in Laboratory Medicine, 2015, 35, 133-163.	1.4	122
70	Resolvin D1 and Resolvin D2 Protect Against Hypoxia/Reoxygenation Induced Lung and Kidney Damage in a Sickle Cell Mouse Model of Acute Vaso-Occlusive Crisis. Blood, 2015, 126, 966-966.	1.4	0
71	Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica, 2014, 99, 267-275.	3.5	89
72	Hereditary xerocytosis revisited. American Journal of Hematology, 2014, 89, 1142-1146.	4.1	47

#	Article	IF	Citations
73	Density-based separation in multiphase systems provides a simple method to identify sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14864-14869.	7.1	107
74	FOXO3â€mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis. American Journal of Hematology, 2014, 89, 954-963.	4.1	73
75	Dehydrated stomatocytic anemia due to the heterozygous mutation R2456H in the mechanosensitive cation channel PIEZO1: a case report. Blood Cells, Molecules, and Diseases, 2014, 52, 53-54.	1.4	28
76	Aging-like Phenotype and Defective Lineage Specification in SIRT1-Deleted Hematopoietic Stem and Progenitor Cells. Stem Cell Reports, 2014, 3, 44-59.	4.8	135
77	Optical Assay of Erythrocyte Function in Banked Blood. Scientific Reports, 2014, 4, 6211.	3.3	39
78	Evaluation of a Density-Based Rapid Diagnostic Test for Sickle Cell Disease in a Clinical Setting in Zambia. PLoS ONE, 2014, 9, e114540.	2.5	42
79	Dietary Ï‰-3 Fatty Acid Supplementation As a Potential New Therapy for Vasculopathy in Sickle Cell Disease: Proof of Concept in a Transgenic Mouse Model. Blood, 2014, 124, 220-220.	1.4	5
80	Senicapoc, a Gardos Channel Inhibitor Developed to Treat Sickle Cell Disease, Exhibits Antimalarial Activity. Blood, 2014, 124, 743-743.	1.4	0
81	Strain-specific variations in cation content and transport in mouse erythrocytes. Physiological Genomics, 2013, 45, 343-350.	2.3	8
82	Pharmacological inhibition of calpainâ€1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease. FASEB Journal, 2013, 27, 750-759.	0.5	28
83	Missense mutations in the ABCB6 transporter cause dominant familialpseudohyperkalemia. American Journal of Hematology, 2013, 88, 66-72.	4.1	67
84	Expansion of host cellular niche can drive adaptation of a zoonotic malaria parasite to humans. Nature Communications, 2013, 4, 1638.	12.8	96
85	Red cell indices in classification and treatment of anemias. Current Opinion in Hematology, 2013, 20, 222-230.	2.5	81
86	Iron Deficiency: What Are the Future Trends in Diagnostics and Therapeutics?. Clinical Chemistry, 2013, 59, 740-745.	3.2	19
87	Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1. Blood, 2013, 121, 3925-3935.	1.4	266
88	Calpain-1 knockout reveals broad effects on erythrocyte deformability and physiology. Biochemical Journal, 2012, 448, 141-152.	3.7	32
89	Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis. Blood, 2012, 120, 3136-3141.	1.4	91
90	Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts. Nature, 2012, 491, 608-612.	27.8	78

#	Article	IF	Citations
91	An appeal to medical journal editors: The need for a full description of laboratory methods and specimen handling in clinical study reports. American Journal of Hematology, 2012, 87, 347-348.	4.1	3
92	Hematologic Aspects of Kidney Disease. , 2012, , 2081-2121.		5
93	Metabolic Pathways Control Normal and Beta-Thalassemic Erythroid Cell Maturation. Blood, 2012, 120, 369-369.	1.4	1
94	Missense Mutations in the ABCB6 Transporter Cause Dominant Familial Pseudohyperkalemia. Blood, 2012, 120, 3184-3184.	1.4	0
95	Resveratrol Induces Erythroid Maturation by Activating FOXO3 and Improves in Vivo Erythropoiesis in Normal and Beta -Thalassemic Mice. Blood, 2012, 120, 3191-3191.	1.4	0
96	The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multiâ€centre CHAMPS trial. British Journal of Haematology, 2011, 152, 771-776.	2.5	30
97	Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. American Journal of Physiology - Cell Physiology, 2011, 301, C1325-C1343.	4.6	24
98	The American Journal of Hematology, 2011 and beyond. American Journal of Hematology, 2011, 86, 1-1.	4.1	2
99	Full-disclosure in industry-sponsored laboratory medicine research studies: Statement by the Consortium of Laboratory Medicine Journal Editors. American Journal of Hematology, 2011, 86, 244-244.	4.1	0
100	Functional characterization and modified rescue of novel AE1 mutation R730C associated with overhydrated cation leak stomatocytosis. American Journal of Physiology - Cell Physiology, 2011, 300, C1034-C1046.	4.6	34
101	Mitochondrial Atpif1 Regulates Heme Synthesis in Developing Erythroblasts. Blood, 2011, 118, 343-343.	1.4	1
102	Pharmacological Inhibition of Calpain-1 Prevents Red Cell Dehydration and Reduces Gardos Channel Activity in a Mouse Model of Sickle Cell Disease. Identification of Druggable Protease Target. Blood, 2011, 118, 852-852.	1.4	0
103	Sequence variation at multiple loci influences red cell hemoglobin concentration. Blood, 2010, 116, e139-e149.	1.4	13
104	ASH 2009 meeting reportâ€"Top 10 clinically oriented abstracts in sickle cell disease. American Journal of Hematology, 2010, 85, 204-206.	4.1	0
105	Early Detection of Response to Hydroxyurea Therapy in Patients with Sickle Cell Anemia. Hemoglobin, 2010, 34, 424-429.	0.8	10
106	Automated reticulocyte counting: state of the art and clinical applications in the evaluation of erythropoiesis. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1369-1380.	2.3	77
107	Hypoxia Activates a Ca2+-Permeable Cation Conductance Sensitive to Carbon Monoxide and to GsMTx-4 in Human and Mouse Sickle Erythrocytes. PLoS ONE, 2010, 5, e8732.	2.5	50
108	atpif1 regulates Mitochondrial Heme Synthesis In Developing Erythroid Cells. Blood, 2010, 116, 163-163.	1.4	0

#	Article	IF	Citations
109	Novel Approaches to Treatment. , 2009, , 755-773.		0
110	An Economic Analysis of Anemia Prevention during Infancy. Journal of Pediatrics, 2009, 154, 44-49.	1.8	17
111	Chemical crosslinking studies with the mouse Kcc1 Kâ€“Cl cotransporter. Blood Cells, Molecules, and Diseases, 2009, 42, 233-240.	1.4	11
112	Effects of Hydroxyurea (HU) and Magnesium Pidolate (Mg) in Hemoglobin SC Disease (HbSC): the â€œCHAMPSâ€•Trial.. Blood, 2009, 114, 819-819.	1.4	5
113	Footprints of Response to Hydroxyurea Are in the Hemogram.. Blood, 2009, 114, 4619-4619.	1.4	0
114	PTPÏµ has a critical role in signaling transduction pathways and phosphoprotein network topology in red cells. Proteomics, 2008, 8, 4695-4708.	2.2	37
115	The American Journal of Hematology in 2007. American Journal of Hematology, 2008, 83, 259-262.	4.1	0
116	Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. British Journal of Haematology, 2008, 142, 3-10.	2.5	17
117	Use of a preoperative bleeding questionnaire in pediatric patients who undergo adenotonsillectomy. Otolaryngology - Head and Neck Surgery, 2008, 139, 546-550.	1.9	40
118	Reduced DIDS-sensitive chloride conductance in Ae1â^'/â^' mouse erythrocytes. Blood Cells, Molecules, and Diseases, 2008, 41, 22-34.	1.4	10
119	Protective effects of phosphodiesteraseâ€4 (PDEâ€4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB Journal, 2008, 22, 1849-1860.	0.5	30
120	An immunoassay for human serum hepcidin at last: Ganz klar?. Blood, 2008, 112, 3922-3923.	1.4	8
121	Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia. British Journal of Haematology, 2007, 140, 071107175539001-???.	2.5	33
122	Quantitative trait loci for peripheral blood cell counts: a study in baboons. Mammalian Genome, 2007, 18, 361-372.	2.2	7
123	Disruption of erythroid K-Cl cotransporters alters erythrocyte volume and partially rescues erythrocyte dehydration in SAD mice. Journal of Clinical Investigation, 2007, 117, 1708-1717.	8.2	80
124	Foxo3 is required for the regulation of oxidative stress in erythropoiesis. Journal of Clinical Investigation, 2007, 117, 2133-2144.	8.2	270
125	Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood, 2006, 108, 123-133.	1.4	192
126	Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. International Journal of Laboratory Hematology, 2006, 28, 303-308.	0.2	194

#	Article	IF	Citations
127	Regulation of Kâ€“Cl cotransport by protein phosphatase 1Î± in mouse erythrocytes. Pflugers Archiv European Journal of Physiology, 2006, 451, 760-768.	2.8	16
128	Quantitative trait loci for baseline erythroid traits. Mammalian Genome, 2006, 17, 298-309.	2.2	16
129	Protective effects ofS-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 291, L457-L465.	2.9	30
130	Effect of complete protein 4.1R deficiency on ion transport properties of murine erythrocytes. American Journal of Physiology - Cell Physiology, 2006, 291, C880-C886.	4.6	23
131	Foxo3 Transcription Factor Regulates Oxidative Stress in In Vivo Erythropoiesis.. Blood, 2006, 108, 468-468.	1.4	0
132	Abnormal regulation of Mg2+ transport via Na/Mg exchanger in sickle erythrocytes. Blood, 2005, 105, 382-386.	1.4	22
133	Genetic influences on peripheral blood cell counts: a study in baboons. Blood, 2005, 106, 1210-1214.	1.4	30
134	Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis. Blood, 2005, 106, 1454-1459.	1.4	29
135	Band 3 â€œNeapolisâ€• ciao ciao aldolase. Blood, 2005, 106, 4024-4025.	1.4	0
136	5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. British Journal of Haematology, 2005, 128, 552-561.	2.5	211
137	Protein phosphatase 1Î± is tyrosine-phosphorylated and inactivated by peroxynitrite in erythrocytes through the src family kinase fgr. Free Radical Biology and Medicine, 2005, 38, 1625-1636.	2.9	24
138	Quantitative trait loci for baseline white blood cell count, platelet count, and mean platelet volume. Mammalian Genome, 2005, 16, 749-763.	2.2	25
139	Screening Healthy Infants for Iron Deficiency Using Reticulocyte Hemoglobin Content. JAMA - Journal of the American Medical Association, 2005, 294, 924.	7.4	146
140	An algorithm using reticulocyte hemoglobin content (CHr) measurement in screening adolescents for iron deficiency. Journal of Adolescent Health, 2005, 36, 529.	2.5	71
141	The Safety and Efficacy of Oral Magnesium Pidolate in Children with Hemoglobin SC Disease.. Blood, 2005, 106, 3777-3777.	1.4	15
142	Physiological Roles of the Intermediate Conductance, Ca2+-activated Potassium Channel Kcnn4. Journal of Biological Chemistry, 2004, 279, 47681-47687.	3.4	173
143	Daily Multivitamins With Iron to Prevent Anemia in High-Risk Infants: A Randomized Clinical Trial. Pediatrics, 2004, 114, 86-93.	2.1	34
144	Iron therapy in the pediatric hemodialysis population. Pediatric Nephrology, 2004, 19, 655-661.	1.7	54

#	Article	IF	Citations
145	Physiology and Pathophysiology of the Erythrocyte Gardos Channel in Hematological Diseases. Advances in Experimental Medicine and Biology, 2004, , 387-388.	1.6	0
146	MSDD1, a Prodrug of 5-Hydroxymethyl-2-Furfural (5HMF), Prolongs the Antisickling Effect of 5HMF in Transgenic Sickle Mice.. Blood, 2004, 104, 3576-3576.	1.4	1
147	Protective Effects of No-Albumin and Albumin on Lung Injury Induced by Hypoxia/Reoxygenation in a Mouse Model of Sickle Cell Disease.. Blood, 2004, 104, 3580-3580.	1.4	0
148	Murine Spherocytosis: Evidence for a Functional Interaction between Protein 4.1 and Na/H Exchange and for a â€œProtectiveâ€•Role of the Gardos Channel Against Hemolysis.. Blood, 2004, 104, 578-578.	1.4	1
149	PDE-4 Inhibitor Rolipram Prevents Hypoxia Induced Pulmonary Hypertension in Transgenic Sickle Cell Sad Mice.. Blood, 2004, 104, 3577-3577.	1.4	0
150	In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica, 2004, 89, 1287-98.	3.5	47
151	Iron Deficiency and Erythropoiesis: New Diagnostic Approaches. Clinical Chemistry, 2003, 49, 1573-1578.	3.2	443
152	Use of reticulocyte hemoglobin content (CHR) measurement in screening for iron deficiency. Journal of Adolescent Health, 2003, 32, 132.	2.5	0
153	Hydroxyurea and Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2003, 289, 1692.	7.4	12
154	Pathophysiological-Based Approaches to Treatment of Sickle Cell Disease. Annual Review of Medicine, 2003, 54, 89-112.	12.2	43
155	Preliminary Assessment of Inhaled Nitric Oxide for Acute Vaso-occlusive Crisis in Pediatric Patients With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2003, 289, 1136.	7.4	158
156	Sickle Cell Disease: From Membrane Pathophysiology to Novel Therapies for Prevention of Erythrocyte Dehydration. Journal of Pediatric Hematology/Oncology, 2003, 25, 927-933.	0.6	64
157	ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood, 2003, 101, 2412-2418.	1.4	180
158	Regulation of K-Cl cotransport during reticulocyte maturation and erythrocyte aging in normal and sickle erythrocytes. American Journal of Physiology - Cell Physiology, 2003, 285, C31-C38.	4.6	30
159	Headpiece domain of dematin is required for the stability of the erythrocyte membrane. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6637-6642.	7.1	68
160	Developing treatment for sickle cell disease. Expert Opinion on Investigational Drugs, 2002, 11, 645-659.	4.1	3
161	Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. Blood, 2002, 99, 1817-1824.	1.4	115
162	Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood, 2002, 99, 357-363.	1.4	94

#	Article	IF	Citations
163	A Hematologic â€œGold Standardâ€•for Iron-deficient States?1. Clinical Chemistry, 2002, 48, 981-982.	3.2	35
164	Therapeutic Strategies for Prevention of Sickle Cell Dehydration. Blood Cells, Molecules, and Diseases, 2001, 27, 71-80.	1.4	21
165	Erythrocyte-active agents and treatment of sickle cell disease. Seminars in Hematology, 2001, 38, 324-332.	3.4	16
166	K-Cl cotransport modulation by intracellular Mg in erythrocytes from mice bred for low and high Mg levels. American Journal of Physiology - Cell Physiology, 2001, 281, C1385-C1395.	4.6	28
167	Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood, 2001, 97, 1451-1457.	1.4	67
168	Hereditary spherocytosis: back to the reticulocytes. Blood, 2001, 98, 2885-2886.	1.4	0
169	Ineffective erythropoiesis in Stat5aâ^'/â^'5bâ^'/â^' mice due to decreased survival of early erythroblasts. Blood, 2001, 98, 3261-3273.	1.4	625
170	A Dominant Negative Mutant of the KCC1 K-Cl Cotransporter. Journal of Biological Chemistry, 2001, 276, 41870-41878.	3.4	93
171	Prevention of Red Cell Dehydration: A Possible New Treatment for Sickle Cell Disease. Fetal and Pediatric Pathology, 2001, 20, 15-25.	0.3	7
172	Erythrocyte[mdash]active agents and treatment of sickle cell disease. Seminars in Hematology, 2001, 38, 324-332.	3.4	9
173	Maximum urine concentrating ability in children with Hb SC disease: Effects of hydroxyurea. , 2000, 64, 47-52.		25
174	Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature, 2000, 403, 776-781.	27.8	1,491
175	Structure and genetic polymorphism of the mouse KCC1 gene. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2000, 1492, 353-361.	2.4	9
176	Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology, 2000, 31, 997-1004.	7.3	426
177	Erythropoietin, iron, and erythropoiesis. Blood, 2000, 96, 823-833.	1.4	317
178	Plasminogen activator inhibitor-1: Defining characteristics in the cerebrospinal fluid of newborns. Journal of Pediatrics, 2000, 137, 132-134.	1.8	8
179	E2F4 Is Essential for Normal Erythrocyte Maturation and Neonatal Viability. Molecular Cell, 2000, 6, 281-291.	9.7	174
180	Reticulocyte Cellular Indices: A New Approach in the Diagnosis of Anemias and Monitoring of Erythropoietic Function. Critical Reviews in Clinical Laboratory Sciences, 2000, 37, 93-130.	6.1	149

#	Article	IF	Citations
181	Erythropoietin, iron, and erythropoiesis. Blood, 2000, 96, 823-833.	1.4	180
182	Serine/threonine protein phosphatases and regulation of K-Cl cotransport in human erythrocytes. American Journal of Physiology - Cell Physiology, 1999, 277, C926-C936.	4.6	76
183	Mouse K-Cl cotransporter KCC1: cloning, mapping, pathological expression, and functional regulation. American Journal of Physiology - Cell Physiology, 1999, 277, C899-C912.	4.6	87
184	Endothelins activate Ca²⁺-gated K⁺channels via endothelin B receptors in CD-1 mouse erythrocytes. American Journal of Physiology - Cell Physiology, 1999, 277, C746-C754.	4.6	50
185	Formation of Dense Erythrocytes in SAD Mice Exposed to Chronic Hypoxia: Evaluation of Different Therapeutic Regimens and of a Combination of Oral Clotrimazole and Magnesium Therapies. Blood, 1999, 94, 4307-4313.	1.4	50
186	Structural and Functional Consequences of Antigenic Modulation of Red Blood Cells With Methoxypoly(Ethylene Glycol). Blood, 1999, 93, 2121-2127.	1.4	130
187	Reticulocyte Hemoglobin Content to Diagnose Iron Deficiency in Children. JAMA - Journal of the American Medical Association, 1999, 281, 2225.	7.4	204
188	Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5aâ^'/â^'5bâ^'/â^' Mice. Cell, 1999, 98, 181-191.	28.9	665
189	Mild spherocytosis and altered red cell ion transport in protein 4.2â€“null mice. Journal of Clinical Investigation, 1999, 103, 1527-1537.	8.2	72
190	Effects of Hydroxyurea (HU) on Maximum Urine Concentrating Ability and Hematological Indices in Children with Hb SC Disease. Pediatric Research, 1999, 45, 148A-148A.	2.3	0
191	Formation of Dense Erythrocytes in SAD Mice Exposed to Chronic Hypoxia: Evaluation of Different Therapeutic Regimens and of a Combination of Oral Clotrimazole and Magnesium Therapies. Blood, 1999, 94, 4307-4313.	1.4	0
192	Positional cloning of the zebrafish sauternes gene: a model for congenital sideroblastic anaemia. Nature Genetics, 1998, 20, 244-250.	21.4	239
193	cDNA Cloning and Functional Characterization of the Mouse Ca2+-gated K+ Channel, mIK1. Journal of Biological Chemistry, 1998, 273, 21542-21553.	3.4	183
194	Clinical Applications of Automated Reticulocyte Indices. Hematology, 1998, 3, 165-176.	1.5	2
195	Autosomal Dominant Distal Renal Tubular Acidosis Is Associated in Three Families with Heterozygosity for the R589H Mutation in the AE1 (Band 3) Clâ^'/HCO3â^'Exchanger. Journal of Biological Chemistry, 1998, 273, 6380-6388.	3.4	167
196	ACTIVATED PROTEIN C CONCENTRATE FOR THE TREATMENT OF MENINGOCOCCAL ENDOTOXIN SHOCK IN RABBITS. Shock, 1998, 9, 138-142.	2.1	40
197	Erythrocyte membrane transport physiology. Current Opinion in Hematology, 1997, 4, 122-127.	2.5	59
198	Degree of Agreement in Plasma Fibrinogen Among Two Functional and One Immunonephelometric Assays. American Journal of Clinical Pathology, 1997, 107, 527-533.	0.7	11

#	Article	IF	Citations
199	Reticulocyte Hemoglobin:An Integrated Parameter for Evaluation of Erythropoietic Activity. American Journal of Clinical Pathology, 1997, 108, 133-142.	0.7	66
200	Dietary Magnesium Supplementation Ameliorates Anemia in a Mouse Model of Î²-Thalassemia. Blood, 1997, 90, 1283-1290.	1.4	49
201	Use of Recombinant Human Erythropoietin Outside the Setting of Uremia. Blood, 1997, 89, 4248-4267.	1.4	244
202	The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. British Journal of Haematology, 1997, 98, 292-294.	2.5	61
203	Cellular effects of hydroxyurea in Hb SC disease. British Journal of Haematology, 1997, 98, 838-844.	2.5	62
204	Dietary Magnesium Supplementation Ameliorates Anemia in a Mouse Model of Î²-Thalassemia. Blood, 1997, 90, 1283-1290.	1.4	0
205	Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I1 and I2 binding sites. European Journal of Pharmacology, 1996, 295, 109-112.	3.5	12
206	Anion Exchanger 1 (Band 3) Is Required to Prevent Erythrocyte Membrane Surface Loss but Not to Form the Membrane Skeleton. Cell, 1996, 86, 917-927.	28.9	267
207	Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.. Journal of Clinical Investigation, 1996, 97, 1227-1234.	8.2	211
208	A High-Performance Liquid Chromatographic Assay for the Determination of Itraconazole Concentration Using Solid-Phase Extraction and Small Sample Volume. Therapeutic Drug Monitoring, 1995, 17, 522-525.	2.0	19
209	Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease. Current Opinion in Hematology, 1995, 2, 132-138.	2.5	60
210	Clotrimazole inhibits cell proliferation in vitro and in vivo. Nature Medicine, 1995, 1, 534-540.	30.7	146
211	Reply to â€œTreating rheumatoid arthritis with clotrimazoleâ€. Nature Medicine, 1995, 1, 978-978.	30.7	0
212	A New Therapeutic Approach for Sickle Cell Disease.. Annals of the New York Academy of Sciences, 1995, 763, 262-271.	3.8	20
213	Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: The importance of iron availability in optimizing response. American Journal of Medicine, 1994, 96, 139-145.	1.5	74
214	Management Training for Pathology Residents:II. Experience with a Focused Curriculum. American Journal of Clinical Pathology, 1994, 101, 564-568.	0.7	20
215	Management Training for Pathology Residents:I. Results of a National Survey. American Journal of Clinical Pathology, 1994, 101, 559-563.	0.7	18
216	Automated Reticulocyte Counting and Measurement of Reticulocyte Cellular Indices:Evaluation of the Miles H*3 Blood Analyzer. American Journal of Clinical Pathology, 1994, 102, 623-632.	0.7	76

#	Article	IF	Citations
217	Effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes. Journal of Cellular Physiology, 1993, 154, 271-280.	4.1	50
218	Membrane properties of erythrocytes in subjects undergoing multiple blood donations with or without recombinant erythropoietin. British Journal of Haematology, 1993, 84, 118-130.	2.5	22
219	Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives.. Journal of Clinical Investigation, 1993, 92, 520-526.	8.2	333
220	Thawing Fresh Frozen Plasma in a Microwave Oven: A Comparison with Thawing in a 37 Â°C Waterbath. American Journal of Clinical Pathology, 1992, 97, 227-232.	0.7	35
221	Treatment of Sickle Cell Anemia with Hydroxyurea and Erythropoietin. New England Journal of Medicine, 1990, 323, 366-372.	27.0	183
222	Characteristics of the volume- and chloride-dependent K transport in human erythrocytes homozygous for hemoglobin C. Journal of Membrane Biology, 1989, 111, 69-81.	2.1	26
223	Ion Content and Transport and the Regulation of Volume in Sickle Cells. Annals of the New York Academy of Sciences, 1989, 565, 96-103.	3.8	21
224	Membrane polyunsaturated fatty acids and lithium-sodium countertransport in human erythrocytes. Life Sciences, 1987, 41, 1171-1178.	4.3	29
225	Regulation of erythrocyte cation and water content in sickle cell anemia. Science, 1986, 232, 388-390.	12.6	258
226	Effect of metabolic depletion on the furosemide-sensitive Na and K fluxes in human red cells. Journal of Membrane Biology, 1985, 86, 145-155.	2.1	26
227	Elevation of red cell sodium-lithium countertransport in hyperlipidemias. Life Sciences, 1985, 36, 649-655.	4.3	72